WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 527716
CAS#: 332863-86-2
Description: MBC-11 is bone resorption factor inhibitor potentially for the treatment of bone lesions, caused by multiple myeloma, metastatic breast and prostate cancer. MBC-11 reduced the incidence of bone metastases to 40%. MBC-11 also significantly decreased bone tumor burden compared to PBS- or zoledronate-treated mice.
MedKoo Cat#: 527716
Name: MBC-11
CAS#: 332863-86-2
Chemical Formula: C11H20N3O14P3
Exact Mass: 511.0158
Molecular Weight: 511.2093
Elemental Analysis: C, 25.84; H, 3.94; N, 8.22; O, 43.81; P, 18.18
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: MBC-11; MBC 11; MBC11
IUPAC/Chemical Name: (1-((((((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)-1-hydroxyethyl)phosphonic acid
InChi Key: HUIKCRXUQCSUJS-ZLRZYOKSSA-N
InChi Code: InChI=1S/C11H20N3O14P3/c1-11(18,29(19,20)21)30(22,23)28-31(24,25)26-4-5-7(15)8(16)9(27-5)14-3-2-6(12)13-10(14)17/h2-3,5,7-9,15-16,18H,4H2,1H3,(H,22,23)(H,24,25)(H2,12,13,17)(H2,19,20,21)/t5-,7-,8+,9-,11?/m1/s1
SMILES Code: O=C1N=C(N)C=CN1[C@H]2[C@H]([C@@H]([C@@H](COP(OP(C(C)(O)P(O)(O)=O)(O)=O)(O)=O)O2)O)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 511.2093 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Reinholz MM, Zinnen SP, Dueck AC, Dingli D, Reinholz GG, Jonart LA, Kitzmann KA, Bruzek AK, Negron V, Abdalla AK, Arendt BK, Croatt AJ, Sanchez-Perez L, Sebesta DP, Lönnberg H, Yoneda T, Nath KA, Jelinek DF, Russell SJ, Ingle JN, Spelsberg TC, Dixon HB, Karpeisky A, Lingle WL. A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone. 2010 Jul;47(1):12-22. doi: 10.1016/j.bone.2010.03.006. PubMed PMID: 20233612; PubMed Central PMCID: PMC2892200.
